Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Challenges and Opportunities for Patient Centric Drug Product Design: Industry Perspectives.

Burke MD, Keeney M, Kleinberg R, Burlage R.

Pharm Res. 2019 Apr 17;36(6):85. doi: 10.1007/s11095-019-2616-5.

PMID:
31001717
2.

Understanding Compression-Induced Amorphization of Crystalline Posaconazole.

Huang C, Klinzing G, Procopio A, Yang F, Ren J, Burlage R, Zhu L, Su Y.

Mol Pharm. 2019 Feb 4;16(2):825-833. doi: 10.1021/acs.molpharmaceut.8b01122. Epub 2019 Jan 8.

PMID:
30575400
3.

Leveraging Digital Health Technologies and Outpatient Sampling in Clinical Drug Development: A Phase I Exploratory Study.

Dockendorf MF, Murthy G, Bateman KP, Kothare PA, Anderson M, Xie I, Sachs JR, Burlage R, Goldman A, Moyer M, Shah JK, Ruba R, Shipley L, Harrelson J.

Clin Pharmacol Ther. 2019 Jan;105(1):168-176. doi: 10.1002/cpt.1142. Epub 2018 Jul 23.

4.

Emerging Microbiological Methods.

Burlage RS.

J Microbiol Methods. 2017 Jul;138:1. doi: 10.1016/j.mimet.2017.05.020. No abstract available.

PMID:
28606384
5.

Does current cefazolin dosing achieve adequate tissue and blood concentrations in obese women undergoing cesarean section?

Kram JJF, Greer DM, Cabrera O, Burlage R, Forgie MM, Siddiqui DS.

Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:334-341. doi: 10.1016/j.ejogrb.2017.01.022. Epub 2017 Jan 19.

PMID:
28122314
6.

Biosensors of bacterial cells.

Burlage RS, Tillmann J.

J Microbiol Methods. 2017 Jul;138:2-11. doi: 10.1016/j.mimet.2016.12.023. Epub 2016 Dec 28. Review.

PMID:
28040457
7.

A novel molecular pattern for methicillin-resistant Staphylococcus aureus in Milwaukee, WI clinical isolates.

Burlage RS, Mahdi N.

Diagn Microbiol Infect Dis. 2009 Mar;63(3):296-301. doi: 10.1016/j.diagmicrobio.2008.11.006. Epub 2008 Dec 30.

PMID:
19117714
8.

Containment of a genetically engineered microorganism during a field bioremediation application.

Ford CZ, Sayler GS, Burlage RS.

Appl Microbiol Biotechnol. 1999 Mar;51(3):397-400.

PMID:
10222588
9.

Organic contaminant detection and biodegradation characteristics.

Burlage RS.

Methods Mol Biol. 1998;102:259-68. No abstract available.

PMID:
9680626
10.
11.

Living biosensors for the management and manipulation of microbial consortia.

Burlage RS, Kuo CT.

Annu Rev Microbiol. 1994;48:291-309. Review.

PMID:
7826008
12.

Bioluminescent sensors for detection of bioavailable Hg(II) in the environment.

Selifonova O, Burlage R, Barkay T.

Appl Environ Microbiol. 1993 Sep;59(9):3083-90.

13.

Molecular approaches for environmental monitoring of microorganisms.

Atlas RM, Sayler G, Burlage RS, Bej AK.

Biotechniques. 1992 May;12(5):706-17. Review. No abstract available.

PMID:
1515138
14.

Comparative genetic organization of incompatibility group P degradative plasmids.

Burlage RS, Bemis LA, Layton AC, Sayler GS, Larimer F.

J Bacteriol. 1990 Dec;172(12):6818-25.

15.

Monitoring of naphthalene catabolism by bioluminescence with nah-lux transcriptional fusions.

Burlage RS, Sayler GS, Larimer F.

J Bacteriol. 1990 Sep;172(9):4749-57.

16.

Rapid, sensitive bioluminescent reporter technology for naphthalene exposure and biodegradation.

King JM, Digrazia PM, Applegate B, Burlage R, Sanseverino J, Dunbar P, Larimer F, Sayler GS.

Science. 1990 Aug 17;249(4970):778-81.

PMID:
17756791
17.
18.

The TOL (pWW0) catabolic plasmid.

Burlage RS, Hooper SW, Sayler GS.

Appl Environ Microbiol. 1989 Jun;55(6):1323-8. Review. No abstract available.

19.

Poppa of the PAC. Interview by Barbara Ehrenreich.

Burlage R.

Health PAC Bull. 1988 Winter;18(4):23-7. No abstract available.

PMID:
10291788
20.

Methods for detecting recombinant DNA in the environment.

Jain RK, Burlage RS, Sayler GS.

Crit Rev Biotechnol. 1988;8(1):33-84. Review.

PMID:
3063388
21.
22.

The walk-in chains: the proprietarization of ambulatory care.

Berliner HS, Burlage RK.

Int J Health Serv. 1987;17(4):585-94.

PMID:
3692644
23.

Proprietary hospital chains and academic medical centers.

Berliner HS, Burlage RK.

Int J Health Serv. 1987;17(1):27-46.

PMID:
3557773
24.
25.

The impact of monoclonal antibodies on the study of human malignant melanoma.

Natali PG, Aguzzi A, Veglia F, Imai K, Burlage RS, Giacomini P, Ferrone S.

J Cutan Pathol. 1983 Dec;10(6):514-28. Review. No abstract available.

PMID:
6198345
26.

CBC: what's preventing a health politics?

Burlage R.

Health PAC Bull. 1979 Nov-Dec;11(2):17-8. No abstract available.

PMID:
10245902
27.

Death against taxes.

Burlage R.

Health PAC Bull. 1979;(81-82):23-6. No abstract available.

PMID:
10240888
28.

What's healthy for business?

Burlage R, Rodberg L.

Health PAC Bull. 1977 Sep-Oct;(78):13-4. No abstract available.

PMID:
10305211
29.

NHI: expanding the horizons.

Rodberg L, Burlage R.

Health PAC Bull. 1977 Jul-Aug;(77):11-2. No abstract available.

PMID:
10305207
30.

Washington: the 9% solution.

Burlage R, Rodberg L.

Health PAC Bull. 1977 Mar-Apr;(75):11-2. No abstract available.

PMID:
10305201
31.

Confrontation. Consumer forces will liberate system.

Burlage RK.

Mod Hosp. 1968 Dec;111(6):81. No abstract available.

PMID:
5718033
32.

The municipal hospital affiliation plan in New York City. A case study and critique.

Burlage RK.

Milbank Mem Fund Q. 1968 Jan;46(1):Suppl:171-201. No abstract available.

PMID:
5644948

Supplemental Content

Loading ...
Support Center